vs
高露洁棕榄（CL）与TENET HEALTHCARE CORP（THC）财务数据对比。点击上方公司名可切换其他公司
TENET HEALTHCARE CORP的季度营收约是高露洁棕榄的1.1倍（$5.5B vs $5.2B），TENET HEALTHCARE CORP净利率更高（11.7% vs -0.7%，领先12.3%），TENET HEALTHCARE CORP同比增速更快（9.0% vs 5.8%），高露洁棕榄自由现金流更多（$1.3B vs $367.0M），过去两年高露洁棕榄的营收复合增速更高（1.6% vs 1.5%）
高露洁棕榄是总部位于美国纽约市曼哈顿中城公园大道的跨国消费品企业，主营家居清洁、医疗护理、个人护理、宠物护理等品类产品的生产、分销及相关服务，旗下产品行销全球多地，在日用消费领域拥有广泛的市场认可度。
Tenet Healthcare Corporation是总部位于美国达拉斯的营利性跨国医疗服务企业，旗下拥有USPI等多个品牌、子公司、合资企业及合作主体，运营65家医院及超过450个医疗设施，还通过旗下Conifer Health Solutions为各类医疗系统及其他客户提供专业医疗支持服务
CL vs THC — 直观对比
营收规模更大
THC
是对方的1.1倍
$5.2B
营收增速更快
THC
高出3.2%
5.8%
净利率更高
THC
高出12.3%
-0.7%
自由现金流更多
CL
多$909.0M
$367.0M
两年增速更快
CL
近两年复合增速
1.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $5.5B |
| 净利润 | $-36.0M | $644.0M |
| 毛利率 | 60.2% | — |
| 营业利润率 | 1.7% | 15.4% |
| 净利率 | -0.7% | 11.7% |
| 营收同比 | 5.8% | 9.0% |
| 净利润同比 | -104.9% | 12.6% |
| 每股收益（稀释后） | $-0.04 | $4.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLTHC
| Q4 25 | $5.2B | $5.5B | ||
| Q3 25 | $5.1B | $5.3B | ||
| Q2 25 | $5.1B | $5.3B | ||
| Q1 25 | $4.9B | $5.2B | ||
| Q4 24 | $4.9B | $5.1B | ||
| Q3 24 | $5.0B | $5.1B | ||
| Q2 24 | $5.1B | $5.1B | ||
| Q1 24 | $5.1B | $5.4B |
净利润CLTHC
| Q4 25 | $-36.0M | $644.0M | ||
| Q3 25 | $735.0M | $579.0M | ||
| Q2 25 | $743.0M | $522.0M | ||
| Q1 25 | $690.0M | $622.0M | ||
| Q4 24 | $738.0M | $572.0M | ||
| Q3 24 | $737.0M | $681.0M | ||
| Q2 24 | $731.0M | $477.0M | ||
| Q1 24 | $683.0M | $2.3B |
毛利率CLTHC
| Q4 25 | 60.2% | — | ||
| Q3 25 | 59.4% | — | ||
| Q2 25 | 60.1% | — | ||
| Q1 25 | 60.8% | — | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 60.6% | — | ||
| Q1 24 | 60.0% | — |
营业利润率CLTHC
| Q4 25 | 1.7% | 15.4% | ||
| Q3 25 | 20.6% | 16.8% | ||
| Q2 25 | 21.1% | 15.6% | ||
| Q1 25 | 21.9% | 18.1% | ||
| Q4 24 | 21.5% | 16.2% | ||
| Q3 24 | 21.2% | 21.3% | ||
| Q2 24 | 21.6% | 14.9% | ||
| Q1 24 | 20.7% | 61.2% |
净利率CLTHC
| Q4 25 | -0.7% | 11.7% | ||
| Q3 25 | 14.3% | 10.9% | ||
| Q2 25 | 14.5% | 9.9% | ||
| Q1 25 | 14.1% | 11.9% | ||
| Q4 24 | 14.9% | 11.3% | ||
| Q3 24 | 14.6% | 13.3% | ||
| Q2 24 | 14.5% | 9.3% | ||
| Q1 24 | 13.5% | 43.5% |
每股收益（稀释后）CLTHC
| Q4 25 | $-0.04 | $4.22 | ||
| Q3 25 | $0.91 | $3.86 | ||
| Q2 25 | $0.91 | $3.14 | ||
| Q1 25 | $0.85 | $4.27 | ||
| Q4 24 | $0.89 | $3.79 | ||
| Q3 24 | $0.90 | $4.89 | ||
| Q2 24 | $0.89 | $2.64 | ||
| Q1 24 | $0.83 | $21.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $2.9B |
| 总债务越低越好 | $7.8B | $13.1B |
| 股东权益账面价值 | $54.0M | $4.2B |
| 总资产 | $16.3B | $29.7B |
| 负债/权益比越低杠杆越低 | 145.17× | 3.10× |
8季度趋势，按日历期对齐
现金及短期投资CLTHC
| Q4 25 | $1.4B | $2.9B | ||
| Q3 25 | $1.3B | $3.0B | ||
| Q2 25 | $1.2B | $2.6B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.3B | $3.0B | ||
| Q3 24 | $1.2B | $4.1B | ||
| Q2 24 | $1.1B | $2.9B | ||
| Q1 24 | $1.1B | $2.5B |
总债务CLTHC
| Q4 25 | $7.8B | $13.1B | ||
| Q3 25 | — | $13.1B | ||
| Q2 25 | — | $13.1B | ||
| Q1 25 | — | $13.1B | ||
| Q4 24 | $7.0B | $13.1B | ||
| Q3 24 | — | $12.8B | ||
| Q2 24 | — | $12.8B | ||
| Q1 24 | — | $12.8B |
股东权益CLTHC
| Q4 25 | $54.0M | $4.2B | ||
| Q3 25 | $856.0M | $4.0B | ||
| Q2 25 | $702.0M | $3.7B | ||
| Q1 25 | $363.0M | $4.2B | ||
| Q4 24 | $212.0M | $4.2B | ||
| Q3 24 | $435.0M | $3.8B | ||
| Q2 24 | $123.0M | $3.5B | ||
| Q1 24 | $230.0M | $3.5B |
总资产CLTHC
| Q4 25 | $16.3B | $29.7B | ||
| Q3 25 | $17.5B | $29.4B | ||
| Q2 25 | $17.5B | $28.7B | ||
| Q1 25 | $16.6B | $29.2B | ||
| Q4 24 | $16.0B | $28.9B | ||
| Q3 24 | $16.8B | $29.4B | ||
| Q2 24 | $16.5B | $29.3B | ||
| Q1 24 | $16.6B | $28.9B |
负债/权益比CLTHC
| Q4 25 | 145.17× | 3.10× | ||
| Q3 25 | — | 3.26× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | 33.04× | 3.14× | ||
| Q3 24 | — | 3.33× | ||
| Q2 24 | — | 3.67× | ||
| Q1 24 | — | 3.70× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5B | $731.0M |
| 自由现金流经营现金流 - 资本支出 | $1.3B | $367.0M |
| 自由现金流率自由现金流/营收 | 24.4% | 6.6% |
| 资本支出强度资本支出/营收 | 3.4% | 6.6% |
| 现金转化率经营现金流/净利润 | — | 1.14× |
| 过去12个月自由现金流最近4个季度 | $3.6B | $2.5B |
8季度趋势，按日历期对齐
经营现金流CLTHC
| Q4 25 | $1.5B | $731.0M | ||
| Q3 25 | $1.3B | $1.1B | ||
| Q2 25 | $884.0M | $936.0M | ||
| Q1 25 | $600.0M | $815.0M | ||
| Q4 24 | $1.3B | $-331.0M | ||
| Q3 24 | $1.2B | $1.0B | ||
| Q2 24 | $990.0M | $747.0M | ||
| Q1 24 | $681.0M | $586.0M |
自由现金流CLTHC
| Q4 25 | $1.3B | $367.0M | ||
| Q3 25 | $1.1B | $778.0M | ||
| Q2 25 | $776.0M | $743.0M | ||
| Q1 25 | $476.0M | $642.0M | ||
| Q4 24 | $1.1B | $-661.0M | ||
| Q3 24 | $1.0B | $829.0M | ||
| Q2 24 | $873.0M | $602.0M | ||
| Q1 24 | $555.0M | $346.0M |
自由现金流率CLTHC
| Q4 25 | 24.4% | 6.6% | ||
| Q3 25 | 21.6% | 14.7% | ||
| Q2 25 | 15.2% | 14.1% | ||
| Q1 25 | 9.7% | 12.3% | ||
| Q4 24 | 21.9% | -13.0% | ||
| Q3 24 | 20.5% | 16.2% | ||
| Q2 24 | 17.3% | 11.8% | ||
| Q1 24 | 11.0% | 6.4% |
资本支出强度CLTHC
| Q4 25 | 3.4% | 6.6% | ||
| Q3 25 | 3.0% | 5.3% | ||
| Q2 25 | 2.1% | 3.7% | ||
| Q1 25 | 2.5% | 3.3% | ||
| Q4 24 | 3.7% | 6.5% | ||
| Q3 24 | 2.7% | 4.2% | ||
| Q2 24 | 2.3% | 2.8% | ||
| Q1 24 | 2.5% | 4.5% |
现金转化率CLTHC
| Q4 25 | — | 1.14× | ||
| Q3 25 | 1.72× | 1.83× | ||
| Q2 25 | 1.19× | 1.79× | ||
| Q1 25 | 0.87× | 1.31× | ||
| Q4 24 | 1.72× | -0.58× | ||
| Q3 24 | 1.58× | 1.53× | ||
| Q2 24 | 1.35× | 1.57× | ||
| Q1 24 | 1.00× | 0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CL
| Other | $3.0B | 58% |
| Pet Nutrition | $1.2B | 23% |
| Oral Personal And Home Care | $1.0B | 20% |
THC
| Other | $2.9B | 52% |
| Health Care Patient Service | $1.4B | 25% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.2B | 22% |
| Health Care Other Sources | $56.0M | 1% |
